Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Celldex Therapeutics, Inc.
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
April 17, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
March 08, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
March 05, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 05, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
February 29, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
February 28, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
February 26, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
February 24, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 06, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
February 05, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
November 27, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
November 07, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
November 07, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
November 06, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
November 05, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 02, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
September 26, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
September 25, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
July 11, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
July 06, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
June 10, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023
June 08, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Therapeutics to Present at Jefferies Healthcare Conference
June 02, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies
May 31, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™
May 15, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 04, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
March 29, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
February 28, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
February 26, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CLDX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.